Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ION-682884 in hereditary transthyretin-mediated amyloid polyneuropathy
NL-OMON55279Phase 3Withdrawn
- Sponsor
- Ionis Pharmaceuticals
- Start
- Mar 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in familial amyloid polyneuropathy (FAP) comparing ION-682884 with inotersen (2 arms). Planned start Mar 2021; status: withdrawn.
02
Drugs
eplonterseninotersen
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on NL-OMON55279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55279.